Search

Your search keyword '"Werner, Lillian"' showing total 330 results
Start Over Author "Werner, Lillian" Publication Year Range Last 10 years
330 results on '"Werner, Lillian"'

1. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Author

Parry, Erin M., Lemvigh, Camilla K., Deng, Stephanie, Dangle, Nathan, Ruthen, Neil, Knisbacher, Binyamin A., Broséus, Julien, Hergalant, Sébastien, Guièze, Romain, Li, Shuqiang, Zhang, Wandi, Johnson, Connor, Long, Jaclyn M., Yin, Shanye, Werner, Lillian, Anandappa, Annabelle, Purroy, Noelia, Gohil, Satyen, Oliveira, Giacomo, Bachireddy, Pavan, Shukla, Sachet A., Huang, Teddy, Khoury, Joseph D., Thakral, Beenu, Dickinson, Michael, Tam, Constantine, Livak, Kenneth J., Getz, Gad, Neuberg, Donna, Feugier, Pierre, Kharchenko, Peter, Wierda, William, Olsen, Lars Rønn, Jain, Nitin, and Wu, Catherine J.

Published
2023
Full Text
View/download PDF

2. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Author

Knudsen, Trine Alma, Skov, Vibe, Stevenson, Kristen, Werner, Lillian, Duke, William, Laurore, Charles, Gibson, Christopher J., Nag, Anwesha, Thorner, Aaron R., Wollison, Bruce, Hansen, Dennis Lund, Ellervik, Christina, El Fassi, Daniel, de Stricker, Karin, Ocias, Lukas Frans, Brabrand, Mette, Bjerrum, Ole Weis, Overgaard, Ulrik Malthe, Frederiksen, Mikael, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Thomassen, Mads, Mourits-Andersen, Torben, Severinsen, Marianne Tang, Stentoft, Jesper, Starklint, Joern, Neuberg, Donna S., Kjaer, Lasse, Larsen, Thomas Stauffer, Hasselbalch, Hans Carl, Lindsley, R. Coleman, and Mullally, Ann

Published
2022
Full Text
View/download PDF

3. Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Author

Miller, Peter G., Qiao, Dandi, Rojas-Quintero, Joselyn, Honigberg, Michael C., Sperling, Adam S., Gibson, Christopher J., Bick, Alexander G., Niroula, Abhishek, McConkey, Marie E., Sandoval, Brittany, Miller, Brian C., Shi, Weiwei, Viswanathan, Kaushik, Leventhal, Matthew, Werner, Lillian, Moll, Matthew, Cade, Brian E., Barr, R. Graham, Correa, Adolfo, Cupples, L. Adrienne, Gharib, Sina A., Jain, Deepti, Gogarten, Stephanie M., Lange, Leslie A., London, Stephanie J., Manichaikul, Ani, O'Connor, George T., Oelsner, Elizabeth C., Redline, Susan, Rich, Stephen S., Rotter, Jerome I., Ramachandran, Vasan, Yu, Bing, Sholl, Lynette, Neuberg, Donna, Jaiswal, Siddhartha, Levy, Bruce D., Owen, Caroline A., Natarajan, Pradeep, Silverman, Edwin K., van Galen, Peter, Tesfaigzi, Yohannes, Cho, Michael H., and Ebert, Benjamin L.

Published
2022
Full Text
View/download PDF

4. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies

Author

Hacken, Elisa ten, Valentin, Rebecca, Regis, Fara Faye D, Sun, Jing, Yin, Shanye, Werner, Lillian, Deng, Jing, Gruber, Michaela, Wong, Jessica, Zheng, Mei, Gill, Amy L, Seiler, Michael, Smith, Peter, Thomas, Michael, Buonamici, Silvia, Ghia, Emanuela M, Kim, Ekaterina, Rassenti, Laura Z, Burger, Jan A, Kipps, Thomas J, Meyerson, Matthew L, Bachireddy, Pavan, Wang, Lili, Reed, Robin, Neuberg, Donna, Carrasco, Ruben D, Brooks, Angela N, Letai, Anthony, Davids, Matthew S, and Wu, Catherine J

Subjects
Hematology, Genetics, Cancer, Rare Diseases, Orphan Drug, Clinical Research, Lymphoma, Adult, Aged, Aged, 80 and over, Alternative Splicing, Animals, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Bridged Bicyclo Compounds, Heterocyclic, Disease Models, Animal, Drug Resistance, Neoplasm, Drug Screening Assays, Antitumor, Epoxy Compounds, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Macrolides, Male, Mice, Mice, Transgenic, Middle Aged, Mitochondria, Mutation, Myeloid Cell Leukemia Sequence 1 Protein, Phosphoproteins, Primary Cell Culture, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-bcl-2, Pyrimidines, RNA Splicing Factors, Spliceosomes, Sulfonamides, Thiophenes, Apoptosis inhibitors, Therapeutics, Transcription
Abstract

The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an Eμ-TCL1-based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases.

Published
2018

5. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation

Author

Sivina, Mariela, Werner, Lillian, Rassenti, Laura, Ferrajoli, Alessandra, Wierda, William G, Keating, Michael J, O'Brien, Susan, Neuberg, Donna, Kipps, Thomas, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Biomarkers, Chemokine CCL3, Chemokine CCL4, Clinical Decision-Making, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Watchful Waiting, chronic lymphocytic leukaemia, C-C motif chemokine ligands3, C-C motif chemokine ligands4, chemokines, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Published
2018

6. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers

Author

Martinez Chanza, Nieves, Werner, Lillian, Plimack, Elizabeth, Yu, Evan Y., Alva, Ajjai S., Crabb, Simon J., Powles, Thomas, Rosenberg, Jonathan E., Baniel, Jack, Vaishampayan, Ulka N., Berthold, Dominik R., Ladoire, Sylvain, Hussain, Syed A., Milowsky, Matthew I., Agarwal, Neeraj, Necchi, Andrea, Pal, Sumanta K., Sternberg, Cora N., Bellmunt, Joaquim, Galsky, Matthew D., and Harshman, Lauren C.

Published
2020
Full Text
View/download PDF

7. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Author

Burger, Jan A, Landau, Dan A, Taylor-Weiner, Amaro, Bozic, Ivana, Zhang, Huidan, Sarosiek, Kristopher, Wang, Lili, Stewart, Chip, Fan, Jean, Hoellenriegel, Julia, Sivina, Mariela, Dubuc, Adrian M, Fraser, Cameron, Han, Yulong, Li, Shuqiang, Livak, Kenneth J, Zou, Lihua, Wan, Youzhong, Konoplev, Sergej, Sougnez, Carrie, Brown, Jennifer R, Abruzzo, Lynne V, Carter, Scott L, Keating, Michael J, Davids, Matthew S, Wierda, William G, Cibulskis, Kristian, Zenz, Thorsten, Werner, Lillian, Dal Cin, Paola, Kharchencko, Peter, Neuberg, Donna, Kantarjian, Hagop, Lander, Eric, Gabriel, Stacey, O'Brien, Susan, Letai, Anthony, Weitz, David A, Nowak, Martin A, Getz, Gad, and Wu, Catherine J

Subjects
Humans, Neoplasm Recurrence, Local, Pyrazoles, Pyrimidines, Apoptosis, Drug Resistance, Neoplasm, Mutation, Adult, Aged, 80 and over, Middle Aged, Female, Male, Protein-Tyrosine Kinases, Leukemia, Lymphocytic, Chronic, B-Cell, Cell Transdifferentiation, Histiocytic Sarcoma, Selection, Genetic, Clonal Evolution, Agammaglobulinaemia Tyrosine Kinase, Aged, and over, Drug Resistance, Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Recurrence, Local, Selection, Genetic
Abstract

Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit an expansion of clones harbouring del(8p) with additional driver mutations (EP300, MLL2 and EIF2A), with one patient developing trans-differentiation into CD19-negative histiocytic sarcoma. Using droplet-microfluidic technology and growth kinetic analyses, we demonstrate the presence of ibrutinib-resistant subclones and estimate subclone size before treatment initiation. Haploinsufficiency of TRAIL-R, a consequence of del(8p), results in TRAIL insensitivity, which may contribute to ibrutinib resistance. These findings demonstrate that the ibrutinib therapy favours selection and expansion of rare subclones already present before ibrutinib treatment, and provide insight into the heterogeneity of genetic changes associated with ibrutinib resistance.

Published
2016

8. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience

Author

Van Dyke, Daniel L, Werner, Lillian, Rassenti, Laura Z, Neuberg, Donna, Ghia, Emanuella, Heerema, Nyla A, Dal Cin, Paola, Aquila, Marie Dell, Sreekantaiah, Chandrika, Greaves, Andrew W, Kipps, Thomas J, and Kay, Neil E

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Lymphoma, Clinical Research, Rare Diseases, Cancer, Hematology, Chromosome Deletion, Chromosomes, Human, Disease-Free Survival, Female, Follow-Up Studies, Humans, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Survival Rate, chronic lymphocytic leukaemia, cytogenetics, leukaemia, fluorescence insitu hybridization, fluorescence in situ hybridization, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well-documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment (TTFT) and overall survival (OS) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization (FISH) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.

Published
2016

11. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy

Author

Murad, Joana M., Baumeister, Susanne H., Werner, Lillian, Daley, Heather, Trébéden-Negre, Hélène, Reder, Jake, Sentman, Charles L., Gilham, David, Lehmann, Frederic, Snykers, Sarah, Sentman, Marie-Louise, Wade, Terri, Schmucker, Adam, Fanger, Michael W., Dranoff, Glenn, Ritz, Jerome, and Nikiforow, Sarah

Published
2018
Full Text
View/download PDF

13. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Author

Cassier, Philippe Alexandre, primary, Dooms, Christophe Alfons, additional, Gazzah, Anas, additional, Felip, Enriqueta, additional, Steeghs, Neeltje, additional, Rohrberg, Kristoffer Staal, additional, De Braud, Filippo G., additional, Solomon, Benjamin J., additional, Schuler, Martin H., additional, Tan, Daniel Shao-Weng, additional, Yamamoto, Noboru, additional, Loong, Herbert H. F., additional, Cho, Byoung Chul, additional, Wolf, Juergen, additional, Lin, Chia-Chi, additional, Negrao, Marcelo Vailati, additional, Werner, Lillian, additional, Cui, Xiaoming, additional, Farago, Anna F., additional, and de Miguel, Maria J., additional

Published
2023
Full Text
View/download PDF

16. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

Author

Rosenberg, Jonathan E., Hahn, Noah M., Regan, Meredith M., Werner, Lillian, Alva, Ajjai, George, Saby, Picus, Joel, Alter, Robert, Balar, Arjun, Hoffman-Censits, Jean, Grivas, Petros, Lauer, Richard, Guancial, Elizabeth A., Hoimes, Christopher, Sonpavde, Guru, Albany, Constantine, Stein, Mark N., Breen, Tim, Jacobs, Cindy, Anderson, Kirsten, Bellmunt, Joaquim, Lalani, Aly-Khan A., Pal, Sumanta, and Choueiri, Toni K.

Published
2018
Full Text
View/download PDF

17. Table S3 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

18. Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table S1 from Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality

Author

Pomerantz, Mark M., primary, Werner, Lillian, primary, Xie, Wanling, primary, Regan, Meredith M., primary, Lee, Gwo-Shu Mary, primary, Sun, Tong, primary, Evan, Carolyn, primary, Petrozziello, Gillian, primary, Nakabayashi, Mari, primary, Oh, William K., primary, Kantoff, Philip W., primary, and Freedman, Matthew L., primary

Published
2023
Full Text
View/download PDF

20. Data from Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality

Author

Pomerantz, Mark M., primary, Werner, Lillian, primary, Xie, Wanling, primary, Regan, Meredith M., primary, Lee, Gwo-Shu Mary, primary, Sun, Tong, primary, Evan, Carolyn, primary, Petrozziello, Gillian, primary, Nakabayashi, Mari, primary, Oh, William K., primary, Kantoff, Philip W., primary, and Freedman, Matthew L., primary

Published
2023
Full Text
View/download PDF

21. Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Author

Baumeister, Susanne H., primary, Murad, Joana, primary, Werner, Lillian, primary, Daley, Heather, primary, Trebeden-Negre, Helene, primary, Gicobi, Joanina K., primary, Schmucker, Adam, primary, Reder, Jake, primary, Sentman, Charles L., primary, Gilham, David E., primary, Lehmann, Frédéric F., primary, Galinsky, Ilene, primary, DiPietro, Heidi, primary, Cummings, Kristen, primary, Munshi, Nikhil C., primary, Stone, Richard M., primary, Neuberg, Donna S., primary, Soiffer, Robert, primary, Dranoff, Glenn, primary, Ritz, Jerome, primary, and Nikiforow, Sarah, primary

Published
2023
Full Text
View/download PDF

22. Data from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Author

McKay, Rana R., primary, Werner, Lillian, primary, Mostaghel, Elahe A., primary, Lis, Rosina, primary, Voznesensky, Olga, primary, Zhang, Zhenwei, primary, Marck, Brett T., primary, Matsumoto, Alvin M., primary, Domachevsky, Liran, primary, Zukotynski, Katherine A., primary, Bhasin, Manoj, primary, Bubley, Glenn J., primary, Montgomery, Bruce, primary, Kantoff, Philip W., primary, Balk, Steven P., primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 6 from Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia

Author

Brown, Jennifer R., primary, Hanna, Megan, primary, Tesar, Bethany, primary, Werner, Lillian, primary, Pochet, Nathalie, primary, Asara, John M., primary, Wang, Yaoyu E., primary, dal Cin, Paola, primary, Fernandes, Stacey M., primary, Thompson, Christina, primary, MacConaill, Laura, primary, Wu, Catherine J., primary, Van de Peer, Yves, primary, Correll, Mick, primary, Regev, Aviv, primary, Neuberg, Donna, primary, and Freedman, Arnold S., primary

Published
2023
Full Text
View/download PDF

24. Supplement - Clean version from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Author

McKay, Rana R., primary, Werner, Lillian, primary, Mostaghel, Elahe A., primary, Lis, Rosina, primary, Voznesensky, Olga, primary, Zhang, Zhenwei, primary, Marck, Brett T., primary, Matsumoto, Alvin M., primary, Domachevsky, Liran, primary, Zukotynski, Katherine A., primary, Bhasin, Manoj, primary, Bubley, Glenn J., primary, Montgomery, Bruce, primary, Kantoff, Philip W., primary, Balk, Steven P., primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

25. Supplement Figure 3 from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Author

McKay, Rana R., primary, Werner, Lillian, primary, Mostaghel, Elahe A., primary, Lis, Rosina, primary, Voznesensky, Olga, primary, Zhang, Zhenwei, primary, Marck, Brett T., primary, Matsumoto, Alvin M., primary, Domachevsky, Liran, primary, Zukotynski, Katherine A., primary, Bhasin, Manoj, primary, Bubley, Glenn J., primary, Montgomery, Bruce, primary, Kantoff, Philip W., primary, Balk, Steven P., primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Data from Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Author

Regan, Meredith M., primary, Jegede, Opeyemi A., primary, Mantia, Charlene M., primary, Powles, Thomas, primary, Werner, Lillian, primary, Motzer, Robert J., primary, Tannir, Nizar M., primary, Lee, Chung-Han, primary, Tomita, Yoshihiko, primary, Voss, Martin H., primary, Plimack, Elizabeth R., primary, Choueiri, Toni K., primary, Rini, Brian I., primary, Hammers, Hans J., primary, Escudier, Bernard, primary, Albiges, Laurence, primary, Huo, Stephen, primary, Del Tejo, Viviana, primary, Stwalley, Brian, primary, Atkins, Michael B., primary, and McDermott, David F., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legends from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

29. Supplement Figure 1 from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Author

McKay, Rana R., primary, Werner, Lillian, primary, Mostaghel, Elahe A., primary, Lis, Rosina, primary, Voznesensky, Olga, primary, Zhang, Zhenwei, primary, Marck, Brett T., primary, Matsumoto, Alvin M., primary, Domachevsky, Liran, primary, Zukotynski, Katherine A., primary, Bhasin, Manoj, primary, Bubley, Glenn J., primary, Montgomery, Bruce, primary, Kantoff, Philip W., primary, Balk, Steven P., primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data from Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance

Author

McKay, Rana R., primary, Kwak, Lucia, primary, Crowdis, Jett P., primary, Sperger, Jamie M., primary, Zhao, Shuang G., primary, Xie, Wanling, primary, Werner, Lillian, primary, Lis, Rosina T., primary, Zhang, Zhenwei, primary, Wei, Xiao X., primary, Lang, Joshua M., primary, Van Allen, Eliezer M., primary, Bhatt, Rupal S., primary, Yu, Evan Y., primary, Nelson, Peter S., primary, Bubley, Glenn J., primary, Montgomery, R. Bruce, primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

31. Supplement Figure 2 from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer

Author

McKay, Rana R., primary, Werner, Lillian, primary, Mostaghel, Elahe A., primary, Lis, Rosina, primary, Voznesensky, Olga, primary, Zhang, Zhenwei, primary, Marck, Brett T., primary, Matsumoto, Alvin M., primary, Domachevsky, Liran, primary, Zukotynski, Katherine A., primary, Bhasin, Manoj, primary, Bubley, Glenn J., primary, Montgomery, Bruce, primary, Kantoff, Philip W., primary, Balk, Steven P., primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Methods, Figures 1-4 and Tables 1 - 5, 7 - 15 from Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia

Author

Brown, Jennifer R., primary, Hanna, Megan, primary, Tesar, Bethany, primary, Werner, Lillian, primary, Pochet, Nathalie, primary, Asara, John M., primary, Wang, Yaoyu E., primary, dal Cin, Paola, primary, Fernandes, Stacey M., primary, Thompson, Christina, primary, MacConaill, Laura, primary, Wu, Catherine J., primary, Van de Peer, Yves, primary, Correll, Mick, primary, Regev, Aviv, primary, Neuberg, Donna, primary, and Freedman, Arnold S., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures 1 - 5, Tables 1 - 2 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 6 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Author

Riester, Markus, primary, Werner, Lillian, primary, Bellmunt, Joaquim, primary, Selvarajah, Shamini, primary, Guancial, Elizabeth A., primary, Weir, Barbara A., primary, Stack, Edward C., primary, Park, Rachel S., primary, O'Brien, Robert, primary, Schutz, Fabio A.B., primary, Choueiri, Toni K., primary, Signoretti, Sabina, primary, Lloreta, Josep, primary, Marchionni, Luigi, primary, Gallardo, Enrique, primary, Rojo, Federico, primary, Garcia, Denise I., primary, Chekaluk, Yvonne, primary, Kwiatkowski, David J., primary, Bochner, Bernard H., primary, Hahn, William C., primary, Ligon, Azra H., primary, Barletta, Justine A., primary, Loda, Massimo, primary, Berman, David M., primary, Kantoff, Philip W., primary, Michor, Franziska, primary, and Rosenberg, Jonathan E., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Author

Amrein, Philip C., primary, Attar, Eyal C., primary, Takvorian, Tak, primary, Hochberg, Ephraim P., primary, Ballen, Karen K., primary, Leahy, Kathleen M., primary, Fisher, David C., primary, LaCasce, Ann S., primary, Jacobsen, Eric D., primary, Armand, Philippe, primary, Hasserjian, Robert P., primary, Werner, Lillian, primary, Neuberg, Donna, primary, and Brown, Jennifer R., primary

Published
2023
Full Text
View/download PDF

40. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

Author

DeAngelo, Daniel J., Brunner, Andrew M., Werner, Lillian, Avigan, David, Fathi, Amir T., Sperling, Adam S., Washington, Abigail, Stroopinsky, Dina, Rosenblatt, Jacalyn, McMasters, Malgorzata, Luptakova, Katarina, Wadleigh, Martha, Steensma, David P., Hobbs, Gabriela S., Attar, Eyal C., Amrein, Philip C., Ebert, Benjamin L., Stone, Richard M., and Ballen, Karen K.

Published
2018
Full Text
View/download PDF

41. Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses

Author

Knudsen, Trine Alma, Skov, Vibe, Stevenson, Kristen, Werner, Lillian, Duke, William, Laurore, Charles, Gibson, Christopher J., Nag, Anwesha, Thorner, Aaron R., Wollison, Bruce, Hansen, Dennis Lund, Ellervik, Christina, Fassi, Daniel El, de Stricker, Karin, Ocias, Lukas Frans, Brabrand, Mette, Bjerrum, Ole Weis, Overgaard, Ulrik Malthe, Frederiksen, Mikael, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Thomassen, Mads, Mourits-Andersen, Torben, Severinsen, Marianne Tang, Stentoft, Jesper, Starklint, Joern, Neuberg, Donna S., Kjaer, Lasse, Larsen, Thomas Stauffer, Hasselbalch, Hans Carl, Lindsley, R. Coleman, Mullally, Ann, Knudsen, Trine Alma, Skov, Vibe, Stevenson, Kristen, Werner, Lillian, Duke, William, Laurore, Charles, Gibson, Christopher J., Nag, Anwesha, Thorner, Aaron R., Wollison, Bruce, Hansen, Dennis Lund, Ellervik, Christina, Fassi, Daniel El, de Stricker, Karin, Ocias, Lukas Frans, Brabrand, Mette, Bjerrum, Ole Weis, Overgaard, Ulrik Malthe, Frederiksen, Mikael, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Thomassen, Mads, Mourits-Andersen, Torben, Severinsen, Marianne Tang, Stentoft, Jesper, Starklint, Joern, Neuberg, Donna S., Kjaer, Lasse, Larsen, Thomas Stauffer, Hasselbalch, Hans Carl, Lindsley, R. Coleman, and Mullally, Ann

Abstract

Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from patients with MPN enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms; #NCT01387763), a randomized controlled phase 3 clinical trial, and 135 samples obtained after 24 months of therapy with recombinant interferon-alpha (IFNa) or hydroxyurea. The primary aim was to evaluate the association between complete clinicohematologic response (CHR) at 24 months and molecular response through sequential assessment of 120 genes using NGS. Among JAK2-mutated patients treated with IFNa, those with CHR had a greater reduction in the JAK2 variant allele frequency (median, 0.29 to 0.07; P, .0001) compared with those not achieving CHR (median, 0.27 to 0.14; P, .0001). In contrast, the CALR variant allele frequency did not significantly decline in those achieving CHR or in those not achieving CHR. Treatment-emergent mutations in DNMT3A were observed more commonly in patients treated with IFNa compared with hydroxyurea (P 5 .04). Furthermore, treatment-emergent DNMT3A mutations were significantly enriched in IFNa–treated patients not attaining CHR (P 5 .02). A mutation in TET2, DNMT3A, or ASXL1 was significantly associated with prior stroke (age-adjusted odds ratio, 5.29; 95% confidence interval, 1.59-17.54; P 5 .007), as was a mutation in TET2 alone (age-adjusted odds ratio, 3.03; 95% confidence interval, 1.03-9.01; P 5 .044). At 24 months, we found mutation-specific response

Published
2022

44. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Author

Regan, Meredith M., primary, Jegede, Opeyemi A., additional, Mantia, Charlene M., additional, Powles, Thomas, additional, Werner, Lillian, additional, Motzer, Robert J., additional, Tannir, Nizar M., additional, Lee, Chung-Han, additional, Tomita, Yoshihiko, additional, Voss, Martin H., additional, Plimack, Elizabeth R., additional, Choueiri, Toni K., additional, Rini, Brian I., additional, Hammers, Hans J., additional, Escudier, Bernard, additional, Albiges, Laurence, additional, Huo, Stephen, additional, Del Tejo, Viviana, additional, Stwalley, Brian, additional, Atkins, Michael B., additional, and McDermott, David F., additional

Published
2021
Full Text
View/download PDF

45. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Author

Regan, Meredith M, primary, Mantia, Charlene M, additional, Werner, Lillian, additional, Tarhini, Ahmad A, additional, Larkin, James, additional, Stephen Hodi, F, additional, Wolchok, Jedd, additional, Postow, Michael A, additional, Stwalley, Brian, additional, Moshyk, Andriy, additional, Ritchings, Corey, additional, Re, Sandra, additional, van Dijck, Wim, additional, McDermott, David F, additional, and Atkins, Michael B, additional

Published
2021
Full Text
View/download PDF

50. Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance

Author

McKay, Rana R., Kwak, Lucia, Crowdis, Jett P., Sperger, Jamie M., Zhao, Shuang G., Xie, Wanling, Werner, Lillian, Lis, Rosina, Zhang, Zhenwei, Wei, Xiao X., Lang, Joshua M., Van Allen, Eliezer M., Bhatt, Rupal S., Yu, Evan Y., Nelson, Peter S., Bubley, Glenn J., Montgomery, R. Bruce, and Taplin, Mary-Ellen

Subjects
Male, Prostatic Neoplasms, Castration-Resistant, Drug Resistance, Neoplasm, Benzamides, Nitriles, Phenylthiohydantoin, Humans, Prospective Studies, Neoplasm Metastasis, Article, Aged
Abstract

PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic castration resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase 2 multicenter study of enzalutamide in metastatic CRPC incorporating tissue and blood biomarkers to dissect mechanisms driving resistance. EXPERIMENTAL DESIGN: Eligible patients with metastatic CRPC underwent a baseline metastasis biopsy and then initiated enzalutamide 160 mg daily. A repeat metastasis biopsy was obtained at radiographic progression from the same site when possible. Blood for circulating tumor cell (CTC) analysis was collected at baseline and progression. The primary objective was to analyze mechanisms of resistance in serial biopsies. Whole exome sequencing was performed on tissue biopsies. CTC samples underwent RNA sequencing. RESULTS: 65 patients initiated treatment, of whom 22 (33.8%) had received prior abiraterone. Baseline biopsies were enriched for alterations in AR (mutations, amplifications) and tumor suppression genes (PTEN, RB1, and TP53) which were observed in 73.1% and 92.3% of baseline biopsies, respectively. Progression biopsies revealed increased AR amplifications (64.7% at progression versus 53.9% at baseline) and BRCA2 alterations (64.7% at progression versus 38.5% at baseline). Genomic analysis of baseline and progression CTC samples demonstrated increased AR splice variants, AR regulated-genes, and neuroendocrine markers at progression. CONCLUSIONS: Our results demonstrate that a large proportion of enzalutamide-treated patients have baseline and progression alterations in the AR pathway and tumor suppressor genes. We demonstrate an increased number of BRCA2 alterations post-enzalutamide highlighting importance of serial tumor sampling in CRPC.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results